Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ãëàçíûå áîëåçíè > Ôîðóì äëÿ îáùåíèÿ âðà÷åé-îôòàëüìîëîãîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 18.07.2018, 19:16
Basta231 Basta231 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 14.03.2018
Ãîðîä: Ñàðàíñê
Ñîîáùåíèé: 10
Ñêàçàë(à) ñïàñèáî: 9
Basta231 *
Õèìè÷åñêèé îæîã

Çäðàâñòâóéòå óâàæàåìûå êîëëåãè! Î÷åíü íðàâèòñÿ ÷èòàòü ôîðóì, è äëÿ ìåíÿ îí ñòàë íàñòîÿùèì îòêðûòèåì!!! Ñïàñèáî âàì!!! Õî÷ó ïîñîâåòîâàòüñÿ ñ âàìè ïî äàëüíåéøåé òàêòèêå â ñëåäóþùèé ñèòóàöèè. 10 äíåé íàçàä íà ïðè¸ì ïðèøëà ïàöèåíòêà ñ õèìè÷åñêèé îæîãîì ðîãîâèöû è êîíúþíêòèâû, ïîëó÷åííûì åé íàêàíóíå óêñóñíîé êèñëîòîé. Ñðàçó ïîñëå ñëó÷èâøåãîñÿ ïàöèåíòêà ñàìà ïðîìûëà ãëàç âîäîé ñ ñîäîé. È îáðàòèëàñü â ãëàçíîé òðàâìïóíêò, ãäå åé íàçíà÷åíî ëå÷åíèå: öèïðîëåò 6 ðàç, òàóôîí 6 ðàç è êîðíåðåãåëü 4 ðàçà. Êî ìíå îíà ïðèøëà íà ñëåäóþùèé äåíü ïîñëå ýòèõ ñîáûòèé. Ïðè îñìîòðå: visus Os -0,7. Ãëàçíàÿ ùåëü ñóæåíà. Õåìîç è âûðàæåííàÿ ãèïåðåìèÿ êîíüþíêòèâû, åäèíè÷íûå ïåòåõèàëüíûå êðîâîèçëèÿíèÿ.  öåíòðå îïòè÷åñêîé çîíû ðîãîâèö
û ýðîçèÿ 1,5*1,5 ìì, ðîãîâèöà ñëåãêà îòå÷íàÿ. Ãëóáëåæàùèå ñðåäû áåç îñîáåííîñòåé.  òå÷åíèå 10 äíåé ïàöèåíòêà äîïîëíèòåëüíî ê âûøåïåðå÷èñëåííûì ïðåïàðàòàì ïîëó÷àëà áàëàðïàí, äåêñàìåòàçîí. Íà ñåãîäíÿøíèé äåíü ýðîçèÿ çàýïèòåëèçèðîâàëàñü, íà ðîãîâèöå âûðàæåííûé îòåê, êîíúþíêòèâà áëåäíàÿ, òîëüêî âî âíóòðåííåì óãëó ðàñøèðåííûå, ïîëíîêðîâíûå ñîñóäû ê-âû, âèçóñ 0,2. Ñåãîäíÿ ðåêîìåíäîâàëà íà÷àòü ôîðñàæ 40% ãëþêîçîé. À ó ñàìîé äóøà áîëèò! Êàê áûòü äàëüøå, êîëëåãè? Ïîäñêàæèòå!!!
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 18.07.2018, 19:31
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,422 ðàç(à) çà 31,767 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
à çà÷åì ãëþêîçíûé ôîðñàæ? êðîìå ñòåðîèäîâ, ïðè õèìè÷åñêîì îæîãå ãëàç ðåêîìåíäóåòñÿ àñêîðáèíêà âíóòðü è ìåñòíî è èíãèáèòîðû êîëëàãåíàçû, ïîäðîáíåå íà àíãëèéñêîì:

Drugs that support repair and minimizing ulceration
Ascorbate: Ascorbate is an essential water soluble vitamin that is a cofactor in rate limiting step of collagen formation. Supplementation of ascorbate by restoring depleted aqueous ascorbate levels reduces the incidence of corneal thinning and ulceration. Oral ascorbate (2 g/day) and topical 10% solution formulated in artificial tears are effective
Collagenase inhibitors: Collagenase inhibitors promote wound healing by inhibiting collagenolytic activity and thus preventing stromal ulceration. Several collagenase inhibitors including cysteine, acetylcysteine, sodium ethylenediamine tetra acetic acid (EDTA), calcium EDTA, penicillamine and citrate have been reported to be efficacious. Only 10-20% acetylcysteine (mucomist) is available commercially. It is an unstable solution and has to be refrigerated and used within 1 week of its preparation.
---
Ocular chemical injuries and their management
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 18.07.2018, 19:42
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,422 ðàç(à) çà 31,767 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïîäðîáíåå î äîçèðîâêå è % ìåñòíûõ ðàñòâîðîâ â òàáëèöå 4 ïî ññûëêå íèæå, òàì æå î èñïîëüçîâàíèè àóòîñûâîðîòêè êðîâè èëè åé æå, íî îáîãàùåííîé òðîìáîöèòàìè, íå çíàþ, íàâåðíîå ó Âàñ íåò òåõíè÷åñêîé âîçìîæíîñòè ãîòîâèòü è ïðèìåíÿòü òðîìáîöèòàðíóþ ïëàçìó:

Current and Upcoming Therapies for Ocular Surface Chemical Injuries
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 18.07.2018, 20:56
Basta231 Basta231 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 14.03.2018
Ãîðîä: Ñàðàíñê
Ñîîáùåíèé: 10
Ñêàçàë(à) ñïàñèáî: 9
Basta231 *
Ôîðñàæ ãëþêîçîé, ýòî âðîäå êàê àíàëîã âàííî÷åê ñ ãëþêîçîé, êîòîðûå èñïîëüçóþòñÿ ïðè îò¸êàõ ðîãîâèöû ( íàïðèìåð ïîñëåîïåðàöèîííûõ). Àñêîðáèíîâóþ êèñëîòó çàêàïûâàòü ðåêîìåíäîâàëà, íî ïàöèåíòêà íå ñìîãëà èç çà æóòêîãî ææåíèÿ îò çàêàïûâàíèÿ, ñ å¸ ñëîâ ãëàç ñèëüíî äåð¸ò, íåâîçìîæíî òåðïåòü. Ñïàñèáî çà ïðåäîñòàâëåííóþ èíôîðìàöèþ, ñåé÷àñ îçíàêîìëþñü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 18.07.2018, 21:12
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,422 ðàç(à) çà 31,767 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ýòî ïîòîìó, ÷òî ðÍ ó ðàñòâîðà àñêîðáèíîâîé êèñëîòû íèçêèé, îôòàëüìîëîãè èñïîëüçóþò 10% ðàñòâîð àñêîðáàòà êàëèÿ, êàê ïðèìåð èç àïòåê Áðèòàíèè:

Potassium Ascorbate (Ascorbic acid)
(eye drops)
Formulary: drops 10% (Unlicensed Product)

Sodium Citrate
(eye drops)
Formulary: drops 10.11% (preservative free) (Unlicensed Product)
Used for acid and alkali burns to the cornea

êàê ïîíèìàþ, åãî â àìáóëàòîðíûõ óñëîâèÿõ ìîæíî ïðèãîòîâèòü èç ðàñòâîðà âèòàìèíà Ñ â àìïóëàõ è ýêâèìîëÿðíîãî êîëè÷åñòâà ïèòüåâîé ñîäû:

Ascorbic acid and potassium bicarbonate are refined to a purity of at least 97% These two chemicals are then mixed in cold water to produce potassium ascorbate. Potassium ascorbate is a less acidic form of vitamin C than ascorbic acid...
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 19.07.2018, 16:55
Basta231 Basta231 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 14.03.2018
Ãîðîä: Ñàðàíñê
Ñîîáùåíèé: 10
Ñêàçàë(à) ñïàñèáî: 9
Basta231 *
Ñïàñèáî çà ðàçúÿñíåíèÿ. ×åñòíî ãîâîðÿ ñàìà ïîáàèâàþñü ðàçâîäèòü. Óçíàþ, ñìîãóò ëè â àïòåêå ó íàñ ýòî ñäåëàòü. Ïðèøëà èäåÿ, à ÷òî åñëè ïåðåä çàêàïûâàíèåì àñêîðáèíêè èñïîëüçîâàòü àíåñòåòèê??
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 19.07.2018, 18:25
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,422 ðàç(à) çà 31,767 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
íå óâåðåí, ÷òî åòî áóäåò õîðîøî, òàê êàê çàêèñëåííàÿ ñðåäà â ãëàçó ìîæåò ïëîõî âëèÿòü íà çàæèâëåíèå, äàæå åñëè ïàöèåíò íå áóäåò ÷óâñòâîâàòü
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 20.07.2018, 21:21
iceloo iceloo âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.02.2011
Ãîðîä: Ñàíêò-Ïåòåðáóðã, Ìîñêâà
Ñîîáùåíèé: 1,060
Ñêàçàë(à) ñïàñèáî: 231
Ïîáëàãîäàðèëè 454 ðàç(à) çà 438 ñîîáùåíèé
iceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåiceloo ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
×òî ñ ðàäóæêîé, å¸ âèäíî? Òàì èðèäîöèêëèòà íåò?
Öèêëîïëåãèêè íå íàçíà÷àëè?
__________________
Ñ óâàæåíèåì, Àéñëó Æàðìóõàíîâà
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 20.07.2018, 23:14
Basta231 Basta231 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 14.03.2018
Ãîðîä: Ñàðàíñê
Ñîîáùåíèé: 10
Ñêàçàë(à) ñïàñèáî: 9
Basta231 *
Ðàäóæêà è çðà÷îê ïðîñìàòðèâàþòñÿ. Ðàäóæêà ñòðóêòóðíà, íå èçìåíåíà â öâåòå, çðà÷îê îêðóãëîé ôîðìû, 3-4ìì, ðåàãèðóåò íà ñâåò æèâî. Ñèíåõèé íåò. ÂÃÄ = 22,0 ïî Ìàêëàêîâó. Öèêëîïëåãèêè íå íàçíà÷àëèñü.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 13:30.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.